Baker DM, Moncure CW, Weymouth LA; American Society for Microbiology. General Meeting.
Abstr Gen Meet Am Soc Microbiol. 1995; 95: 307 (abstract no. V-8).
Virginia Commonwealth University, Medical College of Virginia, Richmond, USA.
The use of recombinant antigen in an EIA assay for the detection of HIV antibody is expected to increase specificity. Recently, Syva has developed a recombinant HIV-1 EIA (EIA1) which we compared to the method currently used in our laboratory, the recombinant HIV1/2 EIA (EIA1/2) by Abbott laboratories. We blindly compared 564 clinical samples. Sera which were routinely tested for HIV by EIA1/2 were saved for testing by EIA1. EIA positive specimens were confirmed by western blot (WB). If the WB was indeterminate (I) or nonreactive (NR), an aliquot was sent to Abbott Virology Reference Laboratory for HIV-2 testing. The EIA1 was performed using the predilution method. Of the 564 serum specimens, 93.1% (525/564) were negative (N) in both assays, 5.3% (30/564) were positive (P) in both assays, 1.6% (9/564) were P only in EIA1/2, and none were P only in EIA1. Of the 9 discrepant specimens, 2 were WB P, 3 were WB I (1 p24 antigen P, 2 p24 antigen N), and 4 were WB NR. None were P for HIV-2 by EIA performed at Abbott. The EIA1 assay correctly identified 4 WB NR specimens as negative, saving time and money; however, this was at the unacceptable cost of missing 3 HIV positive specimens (2 WB P; 1 WB I/p24 antigen P).
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Animals
- Biological Assay
- Blotting, Western
- Equine Infectious Anemia
- HIV
- HIV Antibodies
- HIV Antigens
- HIV Core Protein p24
- HIV Envelope Protein gp120
- HIV Envelope Protein gp160
- HIV Envelope Protein gp41
- HIV Infections
- HIV Seropositivity
- HIV-1
- HIV-2
- Immunoenzyme Techniques
- Sensitivity and Specificity
- immunology
Other ID:
UI: 102215174
From Meeting Abstracts